- Report
- February 2024
- 70 Pages
Egypt
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
France
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Spain
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Iran
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Russia
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Australia
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
China
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
Japan
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4527EUR$4,750USD£3,884GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4527EUR$4,750USD£3,884GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4527EUR$4,750USD£3,884GBP
- Report
- April 2023
- 110 Pages
Global
From €4527EUR$4,750USD£3,884GBP
- Report
- October 2022
- 70 Pages
Africa
From €4527EUR$4,750USD£3,884GBP
- Report
- August 2020
- 150 Pages
Global
From €4051EUR$4,250USD£3,475GBP
Sitagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones in the body. These hormones help to regulate glucose levels in the blood, and can help to reduce the risk of developing type 2 diabetes. Sitagliptin is usually prescribed in combination with other drugs, such as metformin, to help control blood sugar levels. It is also used to treat other conditions, such as polycystic ovary syndrome and non-alcoholic fatty liver disease.
Sitagliptin is available in both oral and injectable forms, and is generally well tolerated with few side effects. It is a relatively new drug, and is becoming increasingly popular as a treatment for endocrine and metabolic disorders.
Some companies in the Sitagliptin market include Merck & Co., Inc., Novartis AG, and Takeda Pharmaceutical Company Limited. Show Less Read more